Skip to main content
. 2022 Sep 27;17(9):e0274599. doi: 10.1371/journal.pone.0274599

Table 2. Symptoms prevalence at baseline (mild or worse) stratified according to haemodialysis schedule.

Mon/Wed/Fri Tue/Thu/Sat Sun/Tue/Thu Total
Number of Patients n = 266 n = 228 n = 23 n = 517
eq5d5l 0.68 0.69 0.74 0.70
Pain (160) 62.0% (138) 63.0% (14) 60.9% (312) 62.4%
Breathlessness (146) 57.3% (126) 57.0% (14) 60.9% (286) 57.3%
Weakness (219) 84.9% (179) 80.3% (18) 78.3% (416) 82.5%
Nausea (99) 38.2% (87) 39.5% (9) 39.1% (195) 38.8%
Vomiting (54) 20.8% (52) 23.5% (4) 17.4% (110) 21.9%
Poor appetite (129) 50.0% (110) 49.5% (12) 52.2% (251) 49.9%
Constipation (97) 37.5% (80) 36.5% (6) 27.3% (183) 36.6%
Sore mouth (119) 45.8% (117) 52.9% (9) 39.1% (245) 48.6%
Drowsiness (165) 64.2% (157) 70.7% (15) 65.2% (337) 67.1%
Poor mobility (177) 68.6% (159) 71.0% (14) 60.9% (350) 69.3%
Itching (169) 65.0% (142) 64.8% (18) 78.3% (329) 65.5%
Difficulty sleeping (170) 65.6% (146) 65.5% (18) 78.3% (334) 66.1%
Restless legs (138) 53.5% (114) 51.8% (16) 69.6% (268) 53.5%
Changes in skin (132) 51.4% (106) 48.2% (11) 50.0% (249) 49.9%
Diarrhoea (82) 31.7% (53) 24.2% (9) 39.1% (144) 28.7%
Anxious (132) 51.0% (105) 47.3% (10) 43.5% (247) 49.0%
Depressed (125) 48.4% (108) 48.6% (9) 39.1% (242) 48.1%